| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Celosin H targets hepatocytes and liver tissue, exhibiting hepatoprotective effects. As a triterpenoid saponin from Celosiae Semen, it may protect liver cells from damage through antioxidant, anti-inflammatory, or other cytoprotective mechanisms. The compound may modulate signaling pathways involved in liver injury and repair. However, specific molecular targets have not been extensively characterized.
|
|---|---|
| ln Vitro |
In vitro, Celosin H is a hepatoprotective triterpenoid saponin. It may protect hepatocytes from damage induced by various hepatotoxic agents. As a triterpenoid saponin, it may exhibit antioxidant, anti-inflammatory, or other cytoprotective activities in cell-based assays. However, detailed in vitro activity data including IC₅₀ values have not been extensively published.
|
| ln Vivo |
In vivo activity data for Celosin H are limited in the published literature. The compound has been primarily characterized as a hepatoprotective triterpenoid saponin from Celosiae Semen. Given its hepatoprotective properties, potential in vivo studies could include rodent models of liver injury induced by hepatotoxic agents such as carbon tetrachloride or acetaminophen. However, such studies have not been extensively reported.
|
| Enzyme Assay |
In vitro assays for Celosin H are not extensively documented. As a hepatoprotective saponin, potential assays could include evaluation of cytoprotective effects in hepatocyte cell lines exposed to hepatotoxic agents. Cells are treated with the compound and hepatotoxic agents, and cell viability, oxidative stress markers, and liver enzyme levels are measured. The compound's structure can be confirmed by NMR and MS. Purity is ≥98%.
|
| Cell Assay |
In vitro cellular assays for Celosin H typically involve evaluation of hepatoprotective effects in liver cell lines such as HepG2 or primary hepatocytes. Cells are treated with the compound and exposed to hepatotoxic agents (e.g., CCl₄, APAP), and cell viability is assessed using MTT or similar assays. Oxidative stress markers and liver enzyme levels are measured. The compound is a white crystalline powder.
|
| Animal Protocol |
In vivo animal experiments for Celosin H have not been extensively reported. Based on its hepatoprotective properties, potential in vivo studies could involve rodent models of liver injury. Animals would be treated with Celosin H prior to or following hepatotoxic agent administration, and endpoints would include liver enzyme levels, histopathology, and oxidative stress markers. However, such studies have not been published for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Celosin H have not been characterized. The compound has a molecular weight of 957.07 g/mol and a molecular formula of C₄₇H₇₂O₂₀. As a large glycosylated triterpenoid saponin, it is expected to have very limited oral bioavailability due to its size and hydrophilic nature. The compound may undergo deglycosylation in the gastrointestinal tract. Storage: powder at -20°C for 3 years or 4°C for 2 years.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Celosin H has not been extensively documented. As a naturally occurring triterpenoid saponin from Celosiae Semen, it is expected to have a relatively favorable safety profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
Celosin H (CAS# 1623405-28-6, molecular formula C₄₇H₇₂O₂₀, molecular weight 957.07) is a novel hepatoprotective triterpenoid saponin from Celosiae Semen. Also known as 青葙苷H. No clinical trials or regulatory approvals have been identified. Purity ≥98%.
|
| Molecular Formula |
C47H72O20
|
|---|---|
| Molecular Weight |
957.06
|
| Exact Mass |
956.461
|
| CAS # |
1623405-28-6
|
| PubChem CID |
162853581
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.48±0.1 g/cm3(Predicted)
|
| Boiling Point |
1048.0±65.0 °C(Predicted)
|
| LogP |
0.5
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
67
|
| Complexity |
1920
|
| Defined Atom Stereocenter Count |
24
|
| SMILES |
C[C@@]12CC[C@@H]3[C@@]([C@H]1CC=C4[C@]2(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)(C[C@@H]([C@@H]([C@@]3(C)C=O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O)O)O)C
|
| InChi Key |
DGLQIOJLFVRFMT-AEWZMEITSA-N
|
| InChi Code |
InChI=1S/C47H72O20/c1-42(2)11-13-47(41(61)67-39-31(56)29(54)28(53)24(17-48)63-39)14-12-45(5)20(21(47)15-42)7-8-26-43(3)16-22(50)36(44(4,19-49)25(43)9-10-46(26,45)6)66-40-33(58)34(32(57)35(65-40)37(59)60)64-38-30(55)27(52)23(51)18-62-38/h7,19,21-36,38-40,48,50-58H,8-18H2,1-6H3,(H,59,60)/t21-,22-,23+,24+,25+,26+,27-,28+,29-,30+,31+,32-,33+,34-,35-,36-,38-,39-,40-,43-,44-,45+,46+,47-/m0/s1
|
| Chemical Name |
(2S,3S,4S,5R,6R)-6-[[(2S,3R,4S,4aR,6aR,6bS,8aS,12aS,14aR,14bR)-4-formyl-2-hydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,5-dihydroxy-4-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0449 mL | 5.2243 mL | 10.4487 mL | |
| 5 mM | 0.2090 mL | 1.0449 mL | 2.0897 mL | |
| 10 mM | 0.1045 mL | 0.5224 mL | 1.0449 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
